Nguyen, Lien D.
Nolte, Luca G.
Tan, Winston J. T.
Giuvelis, Denise
Santos-Sacchi, Joseph
Bilsky, Edward
Ehrlich, Barbara E.
Funding for this research was provided by:
Studienstiftung des Deutschen Volkes
National Institute on Deafness and Other Communication Disorders (DC016318, DC016318)
National Institute of General Medical Sciences (GM103643)
National Institute of Diabetes and Digestive and Kidney Diseases (DK057751)
Article History
Received: 27 August 2020
Accepted: 18 December 2020
First Online: 27 January 2021
Competing interests
: B.E.E is a founder of Osmol Therapeutics, a company that is targeting NCS1 for therapeutic purposes. The remaining authors have declared that no conflict of interest exists.